Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Half-life is one of the most cited pharmacokinetic parameters in research compound documentation — and one of the most misunderstood. Understanding what half-life actually means, and what it implies for dosing, washout periods, and steady-state timing, is foundational to designing valid in vivo research protocols.
What Half-Life Actually Means#
Definition: Half-life (t½) is the time required for plasma concentration of a compound to decrease by 50% from any starting point — assuming first-order elimination kinetics.
First-order kinetics (most compounds):
- Constant fraction of remaining drug eliminated per unit time
- Rate of elimination ∝ plasma concentration
- Results in exponential decay of plasma concentration
- t½ is constant regardless of starting concentration
After each half-life, the fraction remaining:
| Half-lives elapsed | Fraction remaining | % remaining |
|---|---|---|
| 1 | 1/2 | 50% |
| 2 | 1/4 | 25% |
| 3 | 1/8 | 12.5% |
| 4 | 1/16 | 6.25% |
| 5 | 1/32 | ~3% |
Practical rule: After 4–5 half-lives, the compound is considered essentially eliminated (<5% remaining). This determines the washout period required before starting a new experimental phase.
Steady State: Why It Matters#
What steady state means: When dosing repeatedly, drug accumulates until the rate of elimination equals the rate of dosing input. This equilibrium point is steady state.
Time to reach steady state: ~4–5 half-lives from the start of dosing (same principle as elimination: after 4–5 t½ intervals of dosing, concentrations have accumulated to equilibrium).
Importance for research:
- Pharmacodynamic effects are most consistent at steady state
- Avoid measuring endpoints in the accumulation phase (results are not representative)
- Plan research protocols so measurements occur after steady state is achieved
Example — testosterone enanthate (t½ ~4.5 days):
- Steady state achieved after: 4.5 × 5 = ~22 days (~3 weeks of twice-weekly dosing)
- Washout period after stopping: 4.5 × 5 = ~22 days to <5% remaining
Half-Life Reference Table for Common Research Compounds#
Peptides:
| Compound | t½ (approx.) | Route | Notes |
|---|---|---|---|
| BPC-157 | ~4 hours | SC | Short; twice-daily dosing in most studies |
| TB-500 | ~4 hours | SC | Similar to BPC-157 |
| Ipamorelin | ~2 hours | SC | GH peak at Tmax; receptor-mediated effect |
| CJC-1295 (no DAC) | ~30 minutes | SC | Requires twice-daily dosing |
| CJC-1295 with DAC | ~7–8 days | SC | Once-weekly dosing in chronic studies |
| Semaglutide | ~7 days | SC | Fatty acid chain → albumin binding → long t½ |
| Retatrutide | ~5 days | SC | Phase II human PK data |
| GHRP-2 | ~1–2 hours | SC | Similar to ipamorelin |
| HGH Fragment 176-191 | ~1–2 hours | SC | Short; twice-daily for chronic studies |
Anabolic steroids (estimated active t½, not ester hydrolysis t½):
| Compound | Active t½ | Route |
|---|---|---|
| Testosterone Propionate | ~0.8–1.5 days | IM/SC |
| Testosterone Enanthate | ~4–5 days | IM |
| Testosterone Cypionate | ~5–6 days | IM |
| Nandrolone Decanoate | ~6–7 days | IM |
| Trenbolone Acetate | ~1–2 days | IM |
| Trenbolone Enanthate | ~5–6 days | IM |
| Boldenone Undecylenate | ~7–14 days | IM |
| Stanozolol (injectable) | ~1 day | IM |
Half-Life vs. Duration of Effect#
Half-life ≠ duration of action:
This distinction matters for research design. A compound's pharmacodynamic effect may outlast its plasma concentration:
- BPC-157: t½ ~4h in plasma, but the VEGF/angiogenesis cascade it initiates produces effects for days
- Ipamorelin: t½ ~2h, GH pulse lasts ~2–3h, but IGF-1 elevation from repeated dosing accumulates over days
- Testosterone: active t½ ~4.5 days (enanthate), but gene expression changes in muscle/prostate persist beyond plasma elimination
For research protocol design: Use the plasma t½ to determine dosing frequency (to maintain receptor occupancy or sustained plasma levels). Use the biological effect duration to plan endpoint measurement timing.
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science
